Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
RESEARCH TOOLSreports
MIRM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.14 - $53.76
Previous CloseN/A
Volume92.82K
Average Volume (3M)524.13K
Market Cap
$2.55B
Enterprise Value$1.90B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Feb 26, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.07
Shares Outstanding48,004,580
10 Day Avg. Volume487,478
30 Day Avg. Volume524,131
Standard Deviation0.16
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.16
Price to Cash Flow (P/CF)157.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit13.61
Enterprise Value/Ebitda-31.29
Forecast
1Y Price Target
$67.67Price Target Upside29.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Mirum Pharmaceuticals News
PremiumCompany Announcements
Mirum Pharmaceuticals Surpasses 2024 Sales Guidance
---
Bulls Say, Bears Say
Bulls Say
Pipeline DevelopmentInterim analyses from Phase 2b trials of volixibat unlock the next growth opportunities for Mirum Pharmaceuticals — PSC and PBC.
Revenue Growth2025 net product sales guidance of $420-435M exceeds expectations and indicates robust revenue growth.
Bears Say
Regulatory RisksKey risks include sales growth of LIVMARLI significantly below expectations and failure to secure additional regulatory approvals.
---
Ownership Overview
9.65% Insiders
26.31% Mutual Funds
41.45% Other Institutional Investors
10.30% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $23.14 and its highest was $53.76 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Mirum Pharmaceuticals Inc’s market cap is $2.55B.
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is Feb 26, 2025 which is in 4 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on Nov 12, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.449 by $0.149.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is -0.26.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 48,004,580 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.449. Following the earnings report the stock price went up 1.61%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MIRM
---
Mirum Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.67 (29.02% Upside)
$67.67 (29.02% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 77%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 73.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $971.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.74%
12-Months-Change
Fundamentals
Return on Equity
-38.83%
Trailing 12-Months
Asset Growth
2.65%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
---
MIRM Company Deck
---
MIRM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive with significant revenue growth, new product developments, and financial milestones like positive cash flow. However, the company reported a net loss and high operating expenses, which are areas of concern.Read More>---
MIRM Stock 12 Month Forecast
Average Price Target
$67.67
▲(29.02% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Novartis
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering MIRM
1 Year
1 Year Success Rate
30/32 ratings generated profit
1 Year Average Return
+40.33%
reiterated a buy rating last month
Copying Ed Arce's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +40.33% per trade.
---